Clinical Trials Logo

Clinical Trial Summary

This study examines the quality of life in patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma. Collecting quality of life information from patients may help doctors learn more about the most common symptoms and concerns patients with monoclonal gammopathy of unknown significance and smoldering multiple myeloma may have.


Clinical Trial Description

PRIMARY OBJECTIVE: I. Describe baseline and follow up quality of life and monoclonal gammopathy of unknown significance/smoldering multiple myeloma (MGUS/SMM) related anxiety of patients with MGUS/SMM already participating in clinical trials at MD Anderson Cancer Center. SECONDARY OBJECTIVE: I. Identify the most common symptoms/patients concerns to evaluate future interventions for treatment/prevention in this population. OUTLINE: Patients complete quality of life questionnaires over 10-15 minutes at baseline and every 6 months for patients participating in an observational study or every month for patients participating in a treatment study for up to 3 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05136807
Study type Observational
Source M.D. Anderson Cancer Center
Contact Mei Huang
Phone 713-745-9901
Email mhuang3@mdanderson.org
Status Recruiting
Phase
Start date June 7, 2016
Completion date February 2, 2027

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05969821 - Clonal Hematopoiesis of Immunological Significance
Not yet recruiting NCT04702932 - Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
Active, not recruiting NCT03327597 - Iceland Screens, Treats or Prevents Multiple Myeloma N/A
Completed NCT01588015 - Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Phase 1
Completed NCT04439006 - Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization Phase 1
Completed NCT01955395 - Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma N/A
Completed NCT01219010 - A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma Phase 1
Completed NCT01237054 - Imaging in MGUS, SMM and MM Phase 2
Active, not recruiting NCT03855878 - Observation of the Incidence and Natural History of MGUS in Patients Undergoing Weight Reduction Surgery
Recruiting NCT05640843 - A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) N/A
Completed NCT00099047 - Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma Phase 2
Completed NCT00919139 - S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. N/A
Not yet recruiting NCT05114109 - Isatuximab in Type I Cryoglobulinemia Phase 2
Recruiting NCT04114084 - Sleep Apnea in Patients With MGUS and MM
Recruiting NCT06383143 - Promoting Diagnosis and Management of AL in Italy (ProDigALIty)
Withdrawn NCT01571726 - Imaging Studies and the Development of Multiple Myeloma Phase 2
Recruiting NCT01408225 - Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
Active, not recruiting NCT04920084 - A Study of a Plant-Based Diet in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM) N/A
Recruiting NCT06046287 - Daratumumab for Polyneuropathy Associated With MGUS Phase 2
Recruiting NCT03119883 - Dysregulation of Glutamine Activity in the Pathogenesis of Multiple Myeloma N/A